ProSomnus, Inc. (OSAPQ)
Aug 6, 2024 - OSAPQ was delisted (reason: shares cancelled)
0.0140
+0.0004 (2.94%)
Inactive · Last trade price
on Aug 5, 2024
Company Description
ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea.
The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force.
ProSomnus, Inc. is headquartered in Pleasanton, California.
ProSomnus, Inc.
| Country | Canada |
| Founded | 2016 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 136 |
| CEO | Leonard Liptak |
Contact Details
Address: 5675 Gibraltar Dr Pleasanton, California 94588 | |
| Phone | 844-537-5337 |
| Website | prosomnus.com |
Stock Details
| Ticker Symbol | OSAPQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001934064 |
| ISIN Number | US50535E1082 |
| Employer ID | 88-2978216 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Leonard Liptak | Co-Founder, Chief Executive Officer and Director |
| Laing F. Rikkers | Co-Founder and Chair |
| Sung Kim | Co-Founder and Chief Technology Officer |
| Brian B. Dow | Chief Financial Officer and Corporate Secretary |
| Dr. John E. Remmers M.D. | Chief Scientist |
| Heather Whalen | Vice President of Global Marketing Services |
| Dr. Shouresh Charkhandeh D.D.S. | Global Scientific Committee Chair |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 5, 2024 | 15-12G | Securities registration termination |
| Aug 2, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 2, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| Aug 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| Jul 31, 2024 | 8-K | Current Report |
| Jul 31, 2024 | 10-Q | Quarterly Report |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 8-K | Current Report |
| May 20, 2024 | 10-Q | Quarterly Report |